医学
Evolocumab公司
肌痛
埃尔特罗姆博帕格
内科学
血小板
兴奋剂
胃肠病学
免疫性血小板减少症
受体
胆固醇
载脂蛋白B
载脂蛋白A1
作者
Ikuo Inoue,Yasuhiro Takenaka,Yoshitora Kin,Satoshi Yamazaki,Yuichi Ikegami,Daigo Saito,Akira Shimada
摘要
A 72-year-old man with a 10-year history of coronary heart disease started evolocumab treatment once a month after developing excess myalgia due to therapy with a 3-hydroxy-methylglutaryl CoA reductase inhibitor. No side effects such as myalgia symptoms had been reported during the first 14 months of evolocumab treatment; however, he suddenly presented with acute severe thrombocytopenia following the 14th treatment. His platelet count continued to decrease to a nadir of 1,000/ μ L. His platelet-associated immunoglobulin G level had elevated to 790 ng/10 7 cells. He started receiving a combination of steroid therapy, high-dose immunoglobulin therapy, and platelet transfusions, but the first-line therapy was ineffective. He was subsequently treated with a thrombopoietin receptor agonist, and his platelet count recovered to 250,000/ μ L.
科研通智能强力驱动
Strongly Powered by AbleSci AI